PIEZO1 and neoplasm: Targeting PIEZO1 by conjugating its monoclonal antibody with small molecular chemicals such as MMAE can efficiently suppress ESCC tumor cell growth both in vivo and in vitro without inducing any obvious side effects, which represents a promising strategy for improving ESCC patients' prognosis.